Evidence map›Paper›PMID 29861043›Full record

ArticleNeurobiology of aging2018

Evaluating the causality of novel sequence variants in the prion protein gene by example.

Tze How Mok, Carolin Koriath, Zane Jaunmuktane, Tracy Campbell, Susan Joiner, Jonathan D F Wadsworth, Laszlo L P Hosszu, Sebastian Brandner, Ambereen Parvez, Thomas Clement Truelsen and 4 more

Abstract readCase Reports
In one paragraph

Article in Neurobiology of aging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tze How MokMRC Prion Unit, UCL Institute of Prion Diseases, London, UK; National Prion Clinic, National Hospital for Neurology and Neurosurgery, UCLH NHS Foundation Trust, London, UK.
Carolin KoriathDepartment of Neurodegenerative Diseases, UCL Institute of Neurology, London, UK.
Zane JaunmuktaneDepartment of Molecular Neuroscience, UCL Institute of Neurology, London, UK; Division of Neuropathology, National Hospital for Neurology and Neurosurgery, UCLH NHS Foundation Trust, London, UK.
Tracy CampbellMRC Prion Unit, UCL Institute of Prion Diseases, London, UK.
Susan JoinerMRC Prion Unit, UCL Institute of Prion Diseases, London, UK.
Jonathan D F WadsworthMRC Prion Unit, UCL Institute of Prion Diseases, London, UK.
Laszlo L P HosszuMRC Prion Unit, UCL Institute of Prion Diseases, London, UK.
Sebastian BrandnerDepartment of Neurodegenerative Diseases, UCL Institute of Neurology, London, UK; Division of Neuropathology, National Hospital for Neurology and Neurosurgery, UCLH NHS Foundation Trust, London, UK.
Ambereen ParvezDepartment of Neurology, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark.
Thomas Clement TruelsenDepartment of Neurology, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark.
Eva Løbner LundDepartment of Pathology, Rigshospitalet, Copenhagen, Denmark.
Romi SahaHurstwood Park Neurological Centre, Sussex, UK.
John CollingeMRC Prion Unit, UCL Institute of Prion Diseases, London, UK; National Prion Clinic, National Hospital for Neurology and Neurosurgery, UCLH NHS Foundation Trust, London, UK.
Simon MeadMRC Prion Unit, UCL Institute of Prion Diseases, London, UK; National Prion Clinic, National Hospital for Neurology and Neurosurgery, UCLH NHS Foundation Trust, London, UK. Electronic address: s.mead@prion.ucl.ac.uk.

Funding

Medical Research Council MC_U123160655Medical Research Council MC_U123160657Medical Research Council MC_UU_00024/1Medical Research Council MC_UU_00024/5Medical Research Council MC_UU_00024/6Medical Research Council MC_UU_00024/9Medical Research Council MR/M02492X/1
6 · The paper itself

Abstract

The estimation of pathogenicity and penetrance of novel prion protein gene (PRNP) variants presents significant challenges, particularly in the absence of family history, which precludes the application of Mendelian segregation. Moreover, the ambiguities of prion disease pathophysiology renders conventional in silico predictions inconclusive. Here, we describe 2 patients with rapid cognitive decline progressing to akinetic mutism and death within 10 weeks of symptom onset, both of whom possessed the novel T201S variant in PRNP. Clinically, both satisfied diagnostic criteria for probable sporadic Creutzfeldt-Jakob disease and in one, the diagnosis was confirmed by neuropathology. While computational analyses predicted that T201S was possibly deleterious, molecular strain typing, prion protein structural considerations, and calculations leveraging large-scale population data (gnomAD) indicate that T201S is at best either of low penetrance or nonpathogenic. Thus, we illustrate the utility of harnessing multiple lines of prion disease-specific evidence in the evaluation of the T201S variant, which may be similarly applied to assess other novel variants in PRNP.

Indexed as

Amino Acid SubstitutionAgedBrainCreutzfeldt-Jakob SyndromeFemaleHumansMiddle AgedMutation, MissensePrion ProteinsSequence Analysis, ProteinPrion ProteinsPRNP protein, humanCreutzfeldt-Jakob diseaseInherited prion diseaseNovel gene variant interpretationPrion proteinRare gene variant

Identifiers

PMID29861043
PMCPMC6175539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.